Sugi Predict

Sugi Predict / Compounds / SCHEMBL10299459

SCHEMBL10299459

SCHEMBL10299459

CCOC(=O)Cc1ccc(CC)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP4Z1 Q86W10 1/20 0.57
▸ MAPT P10636 2/20 0.54
▸ LMNA P02545 3/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ CYP4F2 P78329 1/20 0.50
▸ CYP4A11 Q02928 1/20 0.50
▸ ALDH1A1 P00352 3/20 0.48
▸ TSHR P16473 2/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ TBXAS1 P24557 1/20 0.47
▸ LIPE Q05469 1/20 0.47
▸ PAM P19021 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ POLB P06746 1/20 0.45
▸ MGAM O43451 1/20 0.44
▸ GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL68851 0.94 CYP4Z1 (0.62) CYP4Z1MAPTLMNASMN1; SMN2CYP4F2
SCHEMBL1107146 0.88 CYP4Z1 (0.57) CYP4Z1MAPTLMNASMN1; SMN2CYP4F2
SCHEMBL68930 0.88 CYP4Z1 (0.57) CYP4Z1MAPTLMNASMN1; SMN2CYP4F2
SCHEMBL6057577 0.88 CYP4F2 (0.59) CYP4Z1MAPTLMNASMN1; SMN2CYP4F2
SCHEMBL2170299 0.86 CA12 (0.61) CYP4Z1MAPTLMNASMN1; SMN2ALDH1A1
SCHEMBL5545889 0.86 CYP4Z1 (0.55) CYP4Z1MAPTLMNASMN1; SMN2CYP4F2
SCHEMBL5034285 0.86 CYP4Z1 (0.59) CYP4Z1MAPTLMNASMN1; SMN2CYP4F2
SCHEMBL6207253 0.86 CYP4Z1 (0.55) CYP4Z1MAPTLMNASMN1; SMN2CYP4F2
SCHEMBL18932531 0.86 CYP4Z1 (0.55) CYP4Z1MAPTLMNASMN1; SMN2CYP4F2
SCHEMBL1179218 0.86 CYP4Z1 (0.55) CYP4Z1MAPTLMNASMN1; SMN2CYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024171769-A1 METHOD FOR PRODUCING ALKYLATED COMPOUND 国立大学法人 東京大学 2024-08-22 — — WO disclosed
US-20180186721-A1 OXIDATIVE COUPLING OF ARYL BORON REAGENTS WITH SP3-CARBON NUCLEOPHILES, AND AMBIENT DECARBOXYLATIVE ARYLATION OF MALONATE HALF-ESTERS VIA OXIDATIVE CATALYSIS THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2018-07-05 — — US disclosed
US-8969362-B2 9-substituted 8-oxoadenine compound ASTRAZENECA AKTIEBOLAG (SE) 2015-03-03 — — US disclosed
US-20140045837-A1 9-Substituted 8-Oxoadenine Compound ASTRAZENECA AKTIEBOLAG (SE) 2014-02-13 — — US disclosed
US-8575180-B2 9-substituted 8-oxoadenine compound ASTRAZENECA AKTIEBOLAG (SE) 2013-11-05 — — US disclosed
US-8293715-B2 10a-Azalide compound crosslinked at 10a- and 12-positions TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 — — US disclosed
EP-1550662-B1 ADENINE COMPOUND AND USE THEREOF DAINIPPON SUMITOMO PHARMA CO (JP) 2012-07-04 — — EP disclosed
US-20110306597-A1 Nicotinamide Derivatives CRAWFORTH JAMES MICHAEL (GB) 2011-12-15 — — US disclosed
US-20110306610-A1 9-SUBSTITUTED 8-OXOADENINE COMPOUND ASTRAZENECA AKTIEBOLAG (SE) 2011-12-15 — — US disclosed
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-09-29 — — US disclosed
US-8012964-B2 9-substituted 8-oxoadenine compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-06 — — US disclosed
US-20110183958-A1 AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. 2011-07-28 — — US disclosed
US-7402674-B2 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments SANOFI-AVENTIS DEUTSCHLAND GMBH, (DE) 2008-07-22 — — US disclosed
US-20070190071-A1 9-Substituted 8-oxoadenine compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-08-16 — — US disclosed
CN-1863793-A Cyclic tertiary amine compound SANKYO CO (JP) 2006-11-15 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS DCLRE1A, AZI2, CHD9 CYP4Z1 718/4885MAPT 4511/4885LMNA 1834/4885
US-20110306610-A1 9-SUBSTITUTED 8-OXOADENINE COMPOUND IFNAR1, IL5, IFNG CYP4Z1 1413/4885MAPT 4844/4885LMNA 4406/4885
US-20070190071-A1 9-Substituted 8-oxoadenine compound IFNAR1, IL5, IFNG CYP4Z1 1413/4885MAPT 4844/4885LMNA 4406/4885
US-20110183958-A1 AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE SCD, SCD5, FADS2 CYP4Z1 970/4885MAPT 3826/4885LMNA 1244/4885
US-20110306597-A1 Nicotinamide Derivatives NNT, NAMPT, NQO1 CYP4Z1 1378/4885MAPT 1518/4885LMNA 1347/4885
US-20180186721-A1 OXIDATIVE COUPLING OF ARYL BORON REAGENTS WITH SP3-CARBON NUCLEOPHILES, AND AMBIENT DECARBOXYLATIVE ARYLATION OF MALONATE HALF-ESTERS VIA OXIDATIVE CATALYSIS SOD1, AOC3, CBR3 CYP4Z1 733/4885MAPT 3964/4885LMNA 3051/4885
US-20140045837-A1 9-Substituted 8-Oxoadenine Compound IFNAR1, IL5, IFNG CYP4Z1 1287/4885MAPT 4853/4885LMNA 4180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.